Shots:
- Eli Lilly and Dicerna have reported the US FDA’s IND acceptance of LY3819469 to treat cardiometabolic diseases. The IND acceptance triggers $10M as a milestone to Dicerna under the companies’ 2018 research collaboration and licensing agreement
- LY3819469 is an investigational GalXC RNAi candidate targeting the LPA gene and is the second clinical-stage candidate to emerge from Dicerna’s collaboration with Lilly
- As per the agreement, Dicerna is eligible to receive ~$350M in development & commercialization milestones for each GalXC hepatocyte target and $355M for each non-hepatocyte target along with royalties on product sales
Click here to read full press release/ article | Ref: Businesswire | Image: Wall Street Journal
The post Eli Lilly to Initiate P-I Study of LY3819469 for Cardiometabolic Diseases first appeared on PharmaShots.
